Lupus & antiphospholipid syndrome
EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update
Methodological detailsguideline update, international Task Force, EULAR standard operating procedures, systematic literature research (January 2019 to March 2024), modified Delphi method
- Guideline update
- International Task Force
- EULAR standard operating procedures
- Systematic literature research (January 2019 to March 2024)
- Modified Delphi method
Recommendations
As issued by the authors
4 overarching principles and 13 recommendations, evaluated for feasibility and impact on clinical care
Use of kidney biopsy for diagnosis; targets of therapy and treatment milestones
Immunomodulatory therapy: antimalarials, GC, immunosuppressives (mycophenolate, CYC, calcineurin inhibitors), biologics (belimumab, obinutuzumab, RTX)
Nonimmune therapy (kidney protection, vaccinations, cardiovascular and bone protection); family planning; management of kidney failure
Guidance on single-agent or early combination immune therapy, GC tapering and withdrawal, duration of immune therapy, and treatment of refractory disease
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →